Hypothalamic hamartomas are non-neoplastic congenital malformations associated with precocious puberty, behavioral disturbances, and gelastic seizures, placing patients into different clinical subgroups at presentation. These lesions arise with either a pedunculated or sessile attachment to the hypothalamus. The MR imaging appearance of these lesions has been described. On T1-weighted images, the lesions are isointense to gray matter. These lesions have typically been described as isointense to gray matter on T2-weighted images, though more recent sources describe T2 hyperintensity. Other criteria for MR imaging diagnosis of hamartoma and exclusion of glioma include lack of enhancement on contrast studies and absence of growth on repeated examinations.

Historically, the histologic composition of these hamartomas has been described as consisting of neurons similar in appearance to hypothalamic neurons. Dysplastic neurons and glial cells have also been described in these lesions. One area of discordance is the amount of glial tissue seen in hypothalamic hamartomas. Studies vary, from those citing glial content similar to that of hypothalamic gray matter to samples with a very large fraction of glial tissue.

Proton MR spectroscopic imaging has allowed supplementation of tumor image characteristics with information regarding tissue metabolite concentration. This spectral information can help distinguish benign pathology from more aggressive lesions. Information obtained from spectroscopic studies may have potential application in the evaluation of hypothalamic hamartomas as well. This study examines the spectral characteristics and T2 appearance of hypothalamic hamartomas and correlates these findings with their histopathologic composition.

Methods

Fourteen patients (5 males, 9 females; ranging from 2 to 17 years of age) who underwent transcallosal resection of hypothalamic hamartoma for refractory epilepsy at this facility between June 2003 and February 2004 were included in this series. These patients had previously undergone imaging and clinical evaluations at other centers and were referred to this center for surgical therapy. Imaging and clinical data were reviewed at this center to confirm the diagnosis of hypothalamic hamartoma.

Imaging Protocol

MR imaging and 1H-MR spectroscopic imaging sequences were performed on 1.5T (10 patients, SIGNA, GE Healthcare, Milwaukee, Wis) and 3T (5 patients, Eclipse, GE Healthcare) scanners with standard quadrature head coils. Imaging included 3T sagittal T2 fast spin-echo (FSE) (TR/TE, 3050/77), axial T1 fast spoiled gradient-recalled echo (TR/TE, 5.1/2.1), and axial and coronal T2 FSE interleaved sequences (TR/TE, 3000/72). Sequences included 1.5T sagittal T1 spin-echo (TR/TE, 450/14), axial 3D spoiled gradient-recalled echo acquisition in the steady state (TR/TE, 23/4.6), and axial and coronal T2 FSE images (TR/TE, 4000/88). Axial or coronal T1- or T2-weighted images were used for MR spectroscopic imaging sequence voxel positioning depending on the conspicuity of the lesion. No intravenous contrast agents were used during these studies.

Received March 18, 2005; accepted after revision August 15.

From the Division of Neuroradiology (D.R.A., J.E.H.), Division of Neuropathology (S.W.C.), Department of Child Neurology (J.F.K.), and the Division of Neurosurgery (H.L.R.), Barrow Neurological Institute, Phoenix, Ariz.

Presented in part at the 35th annual meeting of the Western Neuroradiological Society, October 2003, Kohala Coast, Hawaii.

Address correspondence to Joseph Heiserman, PhD, MD, Division of Neuroradiology, Barrow Neurological Institute, 350 West Thomas Rd, Phoenix, AZ 85013.
MR Spectroscopic Imaging Sequences

Single voxel point-resolved spectroscopy sequences (PRESS) (TR/TE, 2000/35) were obtained for all hamartomas on a 3T scanner when possible. In cases in which a patient required general anesthesia, the 3T scanner was not used because of a lack of compatible anesthesia equipment, and a 1.5T scanner was used. In all cases, the volume of acquisition was specified by using a rectangular region of interest. Voxel sizes were adjusted to best fit the lesion and minimize the inclusion of surrounding brain while including sufficient volume for adequate signal intensity-to-noise ratio, and sizes ranged from 2.6 to 8.4 cm³. In addition, 2D PRESS chemical shift imaging (CSI) sequences (TR/TE, 1200/35) were obtained in 7 patients (3T [n = 4] and 1.5T[n = 3]), and spectra at the level of the amygdala were used to obtain normal gray matter control values.

Pathologic Evaluation

Resected tumor specimens were sectioned, stained (standard hematoxylin-eosin [H&E]), and mounted for microscopic evaluation. All submitted specimens were accepted for pathologic evaluation. The specimens were graded by a neuropathologist (S.W.C.) initially blinded to the results of the imaging evaluation for neuronal/glial fractions, by using a 6-point scale with 1 representing nearly purely neuronal and 6, nearly entirely glial. A relatively uniform distribution of pathologic grades was present in the series.

Data Processing

Dominant myoinositol (mI), choline (Cho), and N-acetylaspartate (NAA) spectral resonances were evaluated by using a creatine (Cr) reference. NAA/Cr, Cho/Cr, and ml/Cr ratios were calculated by using ProbeQuant software (GE Healthcare) provided with both scanners. NAA/Cr, Cho/Cr, and ml/Cr ratios of hamartomas were then compared with corresponding ratios obtained from normal gray matter controls obtained from the amygdala, which was chosen because it is an easily localized gray matter structure of sufficient size to allow valid comparison. In all cases, the amygdala appeared normal on all imaging sequences. Full evaluation of results demonstrated no statistically significant difference between 1.5T and 3T values for corresponding resonances in tumor or normal gray matter controls (P = .24). Therefore, for the purposes of this study, 1.5T and 3T values were pooled.

Relative intensity of lesions on T2-weighted images was also measured against gray matter in the amygdala by using T2 FSE sequences. Three areas of interest were measured within each hamartoma, and an average was calculated. A similar value was calculated for gray matter within the amygdala from the same T2 sequence. Tumor gray matter intensity ratios were then calculated for each patient by dividing average tumor intensity by average gray matter intensity within the amygdala. Again, T2 ratios were pooled because no statistical difference between 1.5T and 3T values was noted (P = .44).

Using this data, we constructed scatterplots comparing spectral ratios and T2 intensity ratios with the 6-point pathologic grading scale. Correlation analysis was used to obtain linear correlation coefficients as a measure of the association of ml/Cr ratio and T2 hyperintensity with pathologic grade.

Results

All hamartomas had a sessile attachment to the hypothalamus, and no pedunculated lesions were noted in this series. Histologic evaluation of the hamartomas demonstrated varying levels of neuronal and glial content. Some tumors exhibited a heterogeneous appearance with small nests of neurons or glial cells on a more homogeneous cellular background. Neuronal elements when present were characteristic, typically smaller than the larger ganglion cells that predominate in the normal hypothalamus. Dysplastic neurons were rarely seen. Glial elements were readily distinguished from astrocytoma, demonstrating small bland nuclei, no atypia or hypercellularity, and little or no proliferative activity on MIB-1 testing. Examples of predominately neuronal and predominately glial histology are given in Fig 1, with corresponding MR spectra and T2 images.

Data from single voxel spectroscopy of the hamartomas demonstrated significant differences in NAA/Cr (P < .001), Cho/Cr (P < .001), and ml/Cr ratios (P < .001) when compared with similar ratios in normal gray matter of the amygdala (Fig 2). NAA ratios were decreased, whereas ml and Cho ratios were increased compared with normal controls. Although all ml ratios were significantly higher than normal, a subgroup was retrospectively identified to be markedly higher than others. Values for ml were then plotted against the neuropathology rating scale. Except for 1 outlier, higher ml/Cr ratios corresponded to increased glial content within the tumor (Fig 3). Correlation of ml/Cr against pathologic grade yielded a linear regression coefficient of 0.74 (P = .004). Removal of the 1 outlier from the dataset increased the correlation coefficient to 0.84 (P = .0006). No association of NAA/Cr or of Cho/Cr with pathologic grade was found.

Appearance of the hamartomas on T2-weighted images also varied. Some lesions were only mildly hyperintense to gray matter on T2 sequences whereas others were notably higher in intensity. The ratio of intensity of hamartoma to gray matter ranged from 1.05 to 1.82 (mean, 1.40; standard deviation, 0.22). Four of the hamartomas in our series exhibited a heterogeneous appearance with areas of varying intensity within the lesion. Intensity ratios were measured with region of interest encompassing most of the lesion without measuring individual areas of heterogeneity. T2 intensity ratios were also plotted against the rating scale of the neuropathologist, and except for the same sample seen as an outlier with ml/Cr, a similar relationship was again noted: Higher T2 intensities correlated with tumors of increased glial content on pathologic evaluation (Fig 4). Correlation analysis yielded a linear correlation coefficient of 0.46 (P = .1), which increased to 0.74 (0.003) when the outlier was removed.

Clinical features of the patients were also examined against the fraction of glial component for correlation. Features including age at onset of epilepsy, duration of epilepsy, severity of epilepsy, presence of precocious puberty, and cognitive function were plotted against the 6-point pathology rating scale. No clear clinical associations existed with the degree of glial abundance on pathology in this series. Currently, this aspect of the pathology (and therefore that of the MR spectroscopy findings) does not prove to be a discriminator for clinical subgroups within the hypothalamic hamartoma spectrum.

Discussion

Prior studies have described the MR imaging appearance and MR spectroscopic properties of hypothalamic hamartomas. Signal intensity on T2-weighted images in published series has varied from isointense to hyperintense when compared with normal gray matter.⁴⁻¹⁰ Our finding of progressive T2 hyper-
intensity with increasing glial content sheds light on this variability of T2 appearance in prior studies.

Previous authors have also described the proton MR spectroscopic properties of hypothalamic hamartomas. Wakai et al.\textsuperscript{14} found decreased NAA/Cr with no alteration of other metabolites in a single case study. Tasch et al.\textsuperscript{15} also confirmed these findings in a spectroscopic study including 5 patients. More recent studies using short TE spectroscopic sequences have found an increase in ml in addition to the NAA reduction. Martin et al.\textsuperscript{7} described increased ml in a hypothalamic hamartoma in a single case study. Freeman et al.\textsuperscript{9} recently confirmed this finding of increased ml levels in a study that included 19 hamartomas. Our data are consistent with these findings.

One area of discordance seen in our study when compared with some of the previous literature is a significant increase in Cho/Cr ratios within hamartomas compared with normal gray matter of the amygdala. In the recent literature, an increase in Cho concentration within hypothalamic hamartomas compared with gray matter of the thalamus but not of the amygdala was reported by Martin et al.\textsuperscript{7} and a similar increase was reported by Akai et al.\textsuperscript{16} Freeman et al.\textsuperscript{9} found no increase in Cho concentration within hypothalamic hamartomas in their series when compared with thalamic gray matter, though differences in Cr concentration between hamartoma and gray matter of the thalamus appear to be associated with some elevation of hamartoma Cho/Cr ratios compared with those in the thalamus in their data. Some of these differences could thus be methodologic, reflecting differences between Cho and

---

**Fig 1.** Photomicrograph (H&E stain) from predominantly neuronal hypothalamic hamartoma (A) with corresponding single voxel MR spectrum (3T) and axial T2-weighted image (B–C). The ml peak is moderately elevated and tumor is slightly hyperintense relative to gray matter on T2-weighted images. Also shown are a photomicrograph from a predominately glial hamartoma (D) with corresponding spectrum (1.5T) and T2-weighted images (E–F). The ml peak is markedly elevated, and the lesion is very hyperintense in comparison to gray matter. Cho is mildly elevated, and NAA is reduced in both cases.

---

**Fig 2.** Graph shows the comparison of spectral ratios within tumor and normal gray matter. A significant decrease is noted in NAA/Cr in the hypothalamic hamartomas compared with normal controls. Significant increases are seen in ml/Cr and Cho/Cr. Horizontal dashes represent 95% confidence intervals.
rapid membrane turnover. Changes in these metabolites with neuronal loss, and elevated Cho has been associated with pathologic conditions. Decreased NAA is generally identified able with MR spectroscopy have been associated with several plasms, multiple sclerosis and clinically isolated syn-

tromes,24,25 multiple sclerosis and clinically isolated syn-

tral resolutions achieved in 1H-MR spectroscopy, the peak are associated with a number of cerebral pathologies. At spec-

ifications available from imaging alone, the results are not highly specific. In particular, elevation of ml can also be seen in some cases of low-grade glioma, even without associated elevation in Cho. Thus, the spectral signature alone cannot reliably differentiate hypothalamic hamartoma from glioma, although such data can supplement contrast-enhanced imaging and re-

peated scans in excluding glioma.

Alterations in cerebral metabolite concentrations detect-

able with MR spectroscopy have been associated with several pathologic conditions. Decreased NAA is generally identified with neuronal loss, and elevated Cho has been associated with rapid membrane turnover.19-21 Changes in these metabolites are associated with a number of cerebral pathologies. At spectral resolutions achieved in 1H-MR spectroscopy, the peak commonly associated with ml contains contributions from glycine and other macromolecular metabolites.22 Prior studies have associated increased ml with gliosis20,22 and also with osmotic shifts, reflecting the putative role of ml as an astro-

cytic osmolyte.23 Elevated ml has been reported in association with a broad spectrum of conditions, including glial neo-

plasms,24,25 multiple sclerosis and clinically isolated syn-

dromes,26 stroke,27 neonatal encephalopathy,28 and Alzhei-

mer disease.29 Our findings extend these observations by identifying an association between both ml level and average T2 signal intensity versus glial fraction within hypothalamic hamartomas.

Although in our series, ml ratio and T2 signal intensity are both positively correlated with increasing glial component within a lesion, several sources of heterogeneity are present in our measurements. The most significant include uncorrected partial volume effects within the spectroscopic voxel and sampling error related to piecemeal removal of only a portion of the hamartoma during transcallosal resection. Additional lesser sources of variability include intrinsic heterogeneity with a given lesion, apparent at histopathologic review and also on the T2-weighted images. An additional source of po-
tential bias arises from the inclusion in our series of only patients selected for surgical therapy for refractory seizures. The pooling of spectroscopic ratio data from 1.5T and 3T imaging systems is also a potential source of heterogeneity; however, the conclusions of this study are separately supported by data from each of the 2 field strengths.

Beyond these sources of heterogeneity, 1 relatively neuro-
al sample demonstrated greater than expected ml ratio and excess T2 hyperintensity. This outlier exhibited mild hetero-
genity on T2-weighted images. Even on retrospective review of the pathologic sample and the spectroscopic data, discordance was still present. We believe that surgical sampling bias is the most likely explanation for this outlier.

Although MR spectroscopy does provide a valuable addi-
tional probe of cerebral pathology, supplementing the information available from imaging alone, the results are not highly specific. In particular, elevation of ml can also be seen in some cases of low-grade glioma, even without associated elevation in Cho. Thus, the spectral signature alone cannot reliably differentiate hypothalamic hamartoma from glioma, although such data can supplement contrast-enhanced imaging and repeated scans in excluding glioma.

Conclusion

Our data reveal a correlation between both ml concentration and T2 signal intensity of hypothalamic hamartomas versus glial fraction as determined by histopathology. No association with clinical subgroups was found in this series; however, these imaging differences could potentially provide a basis for more accurate selection of patients for therapy techniques in the future.

References
